BREAST CANCER:
Post Neo adjuvant
Triple Negative or BRCA Positive Breast Cancer
HOGBRE09-146
PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR+, HER2 Negative with Known BRCA1/2 Mutations (PHH# 10-018)
GASTROINTESTINAL CANCER:
Colon Cancer
Adjuvant:
Stage I or II
NSABP P-5 Statin Polyp Prevention Trial in Patients with Resected Colon Cancer (PHH#10-009)
Adjuvant:
Stage III Colon Cancer
CALGB/SWOG C80702
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer
Second Line Metastatic colorectal cancer KRAS wildtype
ECOG 7208
A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B) in Advanced K-Ras Wild Type Colorectal cancer Following Progression on Bevacizumab Containing Chemoeherpay
Second Line Metastatic Colorectal Cancer KRAS or BRAF mutant
Gilead GS US-295-0203
A Phase 2 Randomized Double Blinded Placebo Controlled Study to Evaluate the Efficacy and safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that has Progressed Following a First Line Oxaliplatin and Fluoropyrimidine Containing Regimen
PANCREATIC CANCER METASTATIC
Gilead GS US-324-0101
A Phase 2 Randomized Double Blinded Placebo Controlled Study to Evaluate the Efficacy and safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
LUNG CANCER
Adjuvant NSCLC Squamous or Non Squamous
ECOG 1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>4cm)-IIIA Non Small Cell Lung Cancer
Stage IIIA and IIIB Unresectable Non Squamous NSCLC
ECOG 6508
A Phase II Study of L-BLP25 and Bevacixumab in Unresectable Stage IIIA and IIIB Non-Squamous Non Small Cell Lung Cancer
Advanced Non-Squamous NSCLC
ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non Squamous NSCLC
ECOG 3508
A Phase II Randomized Trial of Paclitaxel Carboplatin Bevacizumab with or without IMC- A12 in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Second or third line metastatic Non-Squamous NSCLC
ARQ197-A-U302
A Phase III Randomized Double-Blinded Placebo Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib In Previously Treated Subjects With Locally Advanced Or Metastatic Non Squamous Non Small Cell Lung Cancer (NSCLC)
PROSTATE CANCER
Rising PSA After Primary Therapy
ECOG2809
Phase II Randomized Study of MK-2206-Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
For more information, please contact Kathy Litchfield, RN, BS, OCN, Oncology Clinical Trial Coordinator at (717) 724-6765